Flunisolide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Flunisolide: From Asthma/Allergic Rhinitis to Atopic Eczema
One-Sentence Summary
Flunisolide is a synthetic glucocorticoid traditionally used as an inhaled therapy for asthma and as a nasal spray for allergic rhinitis. The TxGNN model predicts it may also be effective for Atopic Eczema, but this direction is currently supported by only 0 clinical trials and 1 observational publication, so the evidence base is thin.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma / allergic rhinitis (inhaled and intranasal corticosteroid) — no formal UK marketing-authorisation text is available in this evidence pack |
| Predicted New Indication | Atopic Eczema |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for flunisolide is not available in this evidence pack. Based on known pharmacology, flunisolide belongs to the glucocorticoid (corticosteroid) class, and its efficacy in asthma (via inhalation) and allergic rhinitis (via nasal spray) is well established; mechanistically this class may be applicable to atopic eczema.
Atopic eczema and flunisolide’s established indications share an underlying Th2-driven inflammatory pathway, and topical corticosteroids are already first-line treatment for atopic eczema — so the pharmacological logic behind the TxGNN prediction is coherent. However, flunisolide itself is formulated for inhaled and intranasal delivery, not for cutaneous application, so there is currently no evidence that the existing formulations could deliver a therapeutic effect at the skin.
Consistent with this, the evidence pack’s own rationale notes: “Flunisolide is a glucocorticoid whose pharmacological class aligns with the anti-inflammatory mechanism of topical steroids used in atopic dermatitis (suppressing Th2 cytokines, reducing inflammatory cell infiltration), but flunisolide itself is formulated for inhalation/nasal use and lacks direct treatment data in a topical formulation.”
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18926054 | 2008 | Cohort | Allergy and Asthma Proceedings | Assessed exhaled breath condensate pH and Th1/Th2/Treg cytokines in children with asthma and atopic dermatitis, evaluating whether a short course of inhaled corticosteroid treatment altered these markers — this is an exploratory biomarker study, not a treatment trial of flunisolide for eczema itself. |
UK Market Information
Flunisolide currently holds no marketing authorisation in the UK (0 licenses on record); market status is Not marketed. No product name, dosage form, or approved-indication text is available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a single observational cytokine-biomarker study rather than any interventional evidence for atopic eczema, and flunisolide’s only established formulations (inhaled/intranasal) do not match the topical route typically required for eczema treatment. Combined with the absence of UK marketing authorisation and missing product-label safety data, the evidence is insufficient to move beyond an initial research question.
To proceed, the following is needed:
- Product label/SmPC warnings and contraindications (currently a blocking data gap)
- Confirmed mechanism-of-action data from DrugBank or another primary source
- A route-compatibility assessment — i.e. whether a topical/dermal formulation of flunisolide is feasible, since existing formulations are inhaled/intranasal
- Dedicated preclinical or clinical evidence testing flunisolide specifically in atopic eczema, rather than inference from asthma/rhinitis biomarker studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.